Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on November 10, 2022. The filing announces the company's financial results for the three and nine months ended September 30, 2022, along with recent corporate updates.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms that results for the three and nine months ended September 30, 2022, were reported.
Guidance, Outlook, and Risks
The filing references "other recent corporate updates" in the press release (Exhibit 99.1) but does not detail specific guidance, outlook, management commentary, risks, or unusual items within the 8-K text itself.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Review Exhibit 99.1 (Press Release) for actual financial figures, as they are absent from the 8-K summary text.
- Confirm the reporting period covers the three and nine months ended September 30, 2022.
- Note that the information in Item 2.02 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.